Previous studies have reported higher GGH expression levels in urothelial, invasive breast, ERG-negative prostate, gallbladder, and gastric cancers compared to corresponding control tissues (Pollard et al., 2009; Silva et al., 2013; Wang et al., 2014; Zali et al., 2019; Muralidharan et al., 2020), which is consistent with our pancancer analysis of TCGA data showing higher GGH expression in numerous cancers including other gynecologic cancers. The gene discussed is GGH; the disease is gastric cancer.